Humanity is aspiring to transcend old age and death. In the 21st century, this might no longer be an unattainable dream.
With everyday exposure to news media, movies, novels and theater, it is easy to assume that artificial intelligence (AI) will be able to provide all-powerful machinery capable of solving matters such as birth, aging, sickness or death — but how far has AI actually progressed in terms of medical science?
As top medical journals show, the progress made by AI goes no further than the ability to more meticulously analyze retinal changes as a result of diabetes in angiographic images; more precisely identify melanoma in dermoscopy images; find lymph node metastasis through analyzing histopathology images of breast cancer patients more accurately and faster than pathologists; forecast blood sugar levels by making calculations based on human genes and gastrointestinal microbiota; and assist oncologists’ decisionmaking by providing more informed and concise suggestions for cancer treatment, an AI technology provided by IBM’s Watson for Oncology.
The IBM Watson after its launch in 2016 received polarized opinions following its failure at the University of Texas’ MD Anderson Cancer Center, with some considering its AI capacity to be immature.
However, the higher the expectations, the greater the disappointment when the technology fails.
Just like the aforementioned advanced medical applications for AI technology, the IBM Watson for Oncology is by no means all-encompassing. It was not designed to diagnose cancers, but to target seven kinds of cancer and provide more in-depth and specific treatment advice. It also cannot give advice on surgery and radiation therapy, nor can it offer suggestions to patients with cancer recurrence or metastasis.
It might sound as if the IBM Watson is useless and not nearly as miraculous as the public believes it to be, but when it comes to treating people diagnosed with early stages of one of the seven targeted kinds of cancer, it provides detailed suggestions for medication and treatment, including chemotherapy, targeted therapy and immunotherapy.
Its suggestions are not only in accordance with the therapy already under way, but it also offers new directions and, in some cases, therapeutic opinions.
Within the scope of its database, IBM Watson is knowledgeable and it keeps “studying” new findings from journals to enhance the precision and subtlety of its analyses.
If the question is whether AI technology can replace an outstanding oncologist, the answer is “of course not.” However, if the question is changed to “Will AI under certain circumstances be able to assist oncologists by providing more precise therapeutic opinions for cancer patients?” then the answer is probably “yes.”
Every time a new technology emerges, public expectations rise too high on the assumption that it will solve all current difficulties. In particular, people find it hard to resist imaginative temptation when it comes to a sexy phrase such as “artificial intelligence.” These wild fantasies often lead to what is known as “technology hype.”
In terms of AI applications in medicine, moderate technology hype could encourage entrepreneurs to make venture investments and bring new capital into the field, thus encouraging the world’s top 10 companies to put a large amount of funds and talent into research. After all, finding the solution to issues related to birth, aging, sickness and death is humankind’s Holy Grail and a tremendously huge business that is growing 10 percent annually.
However, generating too much hype might lead to disappointments and the end of investment and research.
To AI researchers, this scenario sounds all too familiar. Since its emergence, AI has experienced at least two cold spells, both of which began when the technology was over-hyped and bestowed with too many unattainable goals. The Fifth-Generation Computer Systems initiated by Japan, for instance, disappeared quietly into thin air.
The question is whether there will be a third “cold spell” following the most recent emergence. Nevertheless, this possibility looks slim, as the causes of the two previous cold spells have been thoroughly analyzed and their lessons have been learned.
If concise development goals can be established, more rational expectations kept and an early harvest list for specific fields set up beforehand, current hardware processing speed and software maturity mean that the risk for a third cold spell is not great.
In other words, the public might finally be able to enjoy the fruits of AI technology.
Jack Li is dean of Taipei Medical University’s College of Medical Science and founder of the Center for Artificial Intelligence for Medical and Health Innovation.
Translated by Chang Ho-ming
A high-school student surnamed Yang (楊) gained admissions to several prestigious medical schools recently. However, when Yang shared his “learning portfolio” on social media, he was caught exaggerating and even falsifying content, and his admissions were revoked. Now he has to take the “advanced subjects test” scheduled for next month. With his outstanding performance in the general scholastic ability test (GSAT), Yang successfully gained admissions to five prestigious medical schools. However, his university dreams have now been frustrated by the “flaws” in his learning portfolio. This is a wake-up call not only for students, but also teachers. Yang did make a big
As former president Ma Ying-jeou (馬英九) concludes his fourth visit to China since leaving office, Taiwan finds itself once again trapped in a familiar cycle of political theater. The Democratic Progressive Party (DPP) has criticized Ma’s participation in the Straits Forum as “dancing with Beijing,” while the Chinese Nationalist Party (KMT) defends it as an act of constitutional diplomacy. Both sides miss a crucial point: The real question is not whether Ma’s visit helps or hurts Taiwan — it is why Taiwan lacks a sophisticated, multi-track approach to one of the most complex geopolitical relationships in the world. The disagreement reduces Taiwan’s
Former president Ma Ying-jeou (馬英九) is visiting China, where he is addressed in a few ways, but never as a former president. On Sunday, he attended the Straits Forum in Xiamen, not as a former president of Taiwan, but as a former Chinese Nationalist Party (KMT) chairman. There, he met with Chinese People’s Political Consultative Conference Chairman Wang Huning (王滬寧). Presumably, Wang at least would have been aware that Ma had once been president, and yet he did not mention that fact, referring to him only as “Mr Ma Ying-jeou.” Perhaps the apparent oversight was not intended to convey a lack of
Chinese Nationalist Party (KMT) Chairman Eric Chu (朱立倫) last week announced that the KMT was launching “Operation Patriot” in response to an unprecedented massive campaign to recall 31 KMT legislators. However, his action has also raised questions and doubts: Are these so-called “patriots” pledging allegiance to the country or to the party? While all KMT-proposed campaigns to recall Democratic Progressive Party (DPP) lawmakers have failed, and a growing number of local KMT chapter personnel have been indicted for allegedly forging petition signatures, media reports said that at least 26 recall motions against KMT legislators have passed the second signature threshold
RSS